vanoxerine has been researched along with Cocaine Abuse in 13 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Compound (+)-11 showed high affinity and selectivity for DAT over the SERT and, therefore, is a potential candidate for the development of a long-acting cocaine abuse therapeutic agent." | 7.72 | Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents. ( Dersch, CM; Horel, R; Hsin, LW; Jacobson, AE; Prisinzano, T; Rice, KC; Rothman, RB; Wilkerson, CR, 2003) |
| "Both dopamine uptake inhibitors and sigma(1) receptor antagonists have been implicated as potential pharmacotherapeutics for the treatment of cocaine abuse." | 3.72 | Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents. ( Bowen, WD; Cao, J; George, C; Husbands, SM; Katz, JL; Kopajtic, T; Kulkarni, SS; Newman, AH; Williams, W, 2003) |
| " Compound (+)-11 showed high affinity and selectivity for DAT over the SERT and, therefore, is a potential candidate for the development of a long-acting cocaine abuse therapeutic agent." | 3.72 | Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents. ( Dersch, CM; Horel, R; Hsin, LW; Jacobson, AE; Prisinzano, T; Rice, KC; Rothman, RB; Wilkerson, CR, 2003) |
| "In our search for long-acting agents for the treatment of cocaine abuse, a series of optically pure hydroxylated derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (1) and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine (2) (GBR 12909 and GBR 12935, respectively) were synthesized and evaluated in vitro and in vivo." | 3.71 | Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: chiral hydroxyl-containing derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phe ( Baumann, MH; Dersch, CM; Glowa, JR; Hsin, LW; Jacobson, AE; Rice, KC; Rothman, RB; Stafford, D, 2002) |
| "One therapeutic paradigm for cocaine abuse is a 24-h 'agonist' treatment which reduces reinforcing effects in a manner similar to the methadone maintenance model for heroin." | 3.71 | Effect of daily dosing duration of direct and indirect dopamine receptor agonists: cocaine cross-tolerance following chronic regimens. ( Davidson, C; Ellinwood, EH; King, GR; Lee, TH; Yu, GZ, 2002) |
| "Pretreatment with nisoxetine and fluoxetine both attenuated cocaine-induced aversions in a manner comparable to that produced by cocaine itself." | 1.35 | Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. ( Hall, FS; Jones, JD; Rice, K; Riley, AL; Uhl, GR, 2009) |
| "Vanoxerine (GBR-12909) is a high-affinity dopamine reuptake inhibitor that was synthesized in the late 1970s and was initially tested in Europe as a potential antidepressant." | 1.31 | Vanoxerine National Institute on Drug Abuse. ( Preti, A, 2000) |
| "Phentermine was always given as a slow, i." | 1.30 | Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food and cocaine presentation in the rhesus monkey. ( Glowa, JR; Rice, KC; Rothman, RB; Wojnicki, FH, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, DB | 2 |
| Matecka, D | 1 |
| Zhang, Y | 1 |
| Hsin, LW | 3 |
| Dersch, CM | 3 |
| Stafford, D | 3 |
| Glowa, JR | 4 |
| Rothman, RB | 5 |
| Rice, KC | 5 |
| Baumann, MH | 2 |
| Jacobson, AE | 2 |
| Cao, J | 1 |
| Kulkarni, SS | 1 |
| Husbands, SM | 1 |
| Bowen, WD | 1 |
| Williams, W | 1 |
| Kopajtic, T | 1 |
| Katz, JL | 1 |
| George, C | 1 |
| Newman, AH | 2 |
| Jang, EY | 1 |
| Ryu, YH | 1 |
| Lee, BH | 1 |
| Chang, SC | 1 |
| Yeo, MJ | 1 |
| Kim, SH | 1 |
| Folsom, RJ | 1 |
| Schilaty, ND | 1 |
| Kim, KJ | 1 |
| Yang, CH | 1 |
| Steffensen, SC | 1 |
| Kim, HY | 1 |
| Jones, JD | 1 |
| Hall, FS | 1 |
| Uhl, GR | 1 |
| Rice, K | 1 |
| Riley, AL | 1 |
| Ellinwood, EH | 1 |
| Davidson, C | 1 |
| Yu, GZ | 1 |
| King, GR | 1 |
| Lee, TH | 1 |
| Prisinzano, T | 1 |
| Wilkerson, CR | 1 |
| Horel, R | 1 |
| Prisinzano, TE | 1 |
| Wojnicki, FH | 1 |
| Schenk, S | 1 |
| Partridge, B | 1 |
| Shippenberg, TS | 1 |
| Preti, A | 1 |
| Carboni, E | 1 |
| Spielewoy, C | 1 |
| Vacca, C | 1 |
| Nosten-Bertrand, M | 1 |
| Giros, B | 1 |
| Di Chiara, G | 1 |
1 review available for vanoxerine and Cocaine Abuse
| Article | Year |
|---|---|
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction.
Topics: Animals; Behavior, Animal; Benztropine; Cocaine-Related Disorders; Conditioning, Psychological; Dise | 2008 |
12 other studies available for vanoxerine and Cocaine Abuse
| Article | Year |
|---|---|
Oxygenated analogues of 1-[2-(Diphenylmethoxy)ethyl]- and 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909) as potential extended-action cocaine-abuse therapeutic agents.
Topics: Animals; Carrier Proteins; Cocaine-Related Disorders; Delayed-Action Preparations; Dopamine; Dopamin | 1999 |
Development of long-acting dopamine transporter ligands as potential cocaine-abuse therapeutic agents: chiral hydroxyl-containing derivatives of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-(diphenylmethoxy)ethyl]-4-(3-phe
Topics: Animals; Behavior, Animal; Benzhydryl Compounds; Cocaine-Related Disorders; Dopamine Plasma Membrane | 2002 |
Dual probes for the dopamine transporter and sigma1 receptors: novel piperazinyl alkyl-bis(4'-fluorophenyl)amine analogues as potential cocaine-abuse therapeutic agents.
Topics: Animals; Binding, Competitive; Brain; Cocaine-Related Disorders; Crystallography, X-Ray; Dopamine; D | 2003 |
Involvement of reactive oxygen species in cocaine-taking behaviors in rats.
Topics: Animals; Antioxidants; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Cyclic N-Oxides; D | 2015 |
Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion.
Topics: Animals; Cocaine; Cocaine-Related Disorders; Conditioning, Psychological; Dopamine; Dopamine Uptake | 2009 |
Effect of daily dosing duration of direct and indirect dopamine receptor agonists: cocaine cross-tolerance following chronic regimens.
Topics: Analysis of Variance; Animals; Area Under Curve; Autoreceptors; Benzothiazoles; Cocaine; Cocaine-Rel | 2002 |
Synthesis and dopamine transporter affinity of chiral 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(2-hydroxypropyl)piperazines as potential cocaine abuse therapeutic agents.
Topics: Animals; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Dopamine Plasma Membrane Transpo | 2003 |
Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food and cocaine presentation in the rhesus monkey.
Topics: Animals; Behavior, Animal; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Co | 1999 |
U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking.
Topics: Amphetamine; Animals; Behavior, Addictive; Benzeneacetamides; Cocaine-Related Disorders; Dopamine An | 1999 |
Response requirements and unit dose modify the effects of GBR 12909 on cocaine-maintained behavior.
Topics: Animals; Central Nervous System Stimulants; Cocaine; Cocaine-Related Disorders; Disease Models, Anim | 2000 |
Vanoxerine National Institute on Drug Abuse.
Topics: Animals; Clinical Trials as Topic; Cocaine-Related Disorders; Contraindications; Dopamine Uptake Inh | 2000 |
Cocaine and amphetamine increase extracellular dopamine in the nucleus accumbens of mice lacking the dopamine transporter gene.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Carrier Proteins; Chromatography, High Pressure | 2001 |